A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour[Substudy Number 01(NSCLC)]
Sponsor: Nanjing Leads Biolabs Co.,Ltd
Listed as NCT06783647, this PHASE2 trial focuses on Advanced Solid Tumour and remains actively recruiting participants. Sponsored by Nanjing Leads Biolabs Co.,Ltd, it has been updated 7 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
-
Nov 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Jun 2025 — Aug 2025 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2025 — Jun 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Nanjing Leads Biolabs Co.,Ltd
- Sun Yat-sen University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changsha, China , Chengdu, China , Fuzhou, China , Ganzhou, China , Guangzhou, China , Guilin, China , Hangzhou, China , Harbin, China , Hefei, China and 12 more locations